M&A deal growth, the AI revolution, and the market surge of GLP-1 weight-loss medicines represent a trio of hot trends propelling the biopharmaceutical industry.
Tag Archive for: biopharma
Despite a surge in the financial markets, multiple big pharma companies have announced hundreds or even thousands of cuts. Experts hope for a better second half of the year.
Mergers and acquisitions (M&As) in the biopharmaceutical industry have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023. In Q1 2024 alone, biopharmaceutical M&A reached a total deal value of $43.5 billion, with a 71% year-on-year (YoY) increase of mega deals that were valued at $1 billion or more compared to Q1 2023, reveals GlobalData.
Since the calendar turned to 2024, we have seen some blockbusters, including Novo Nordisk’s $16.5 billion purchase agreement for Catalent and the closing of Bristol Myers Squibb’s $4.8 billion acquisition of Mirati Therapeutics.
The biopharma industry has been largely underfunding vaccine development despite its strong potential to prevent diseases and reduce hospitalizations and deaths, according to a report published by industry advocacy group Biotechnology Innovation Organization.
Last year was a tough one for the biopharma industry. There are signs of recovery, however, with PwC predicting that mergers and acquisitions across the pharmaceutical and life sciences industry will reach a “healthy” level in 2024. Will the job market follow suit?
All three companies closed out the year, which saw significant growth in mergers and acquisitions, with high-value deals that could potentially set the tone for M&A in 2024.
The agency is investigating reports of secondary blood cancers in patients who have received certain CAR T cell therapies, but experts say the risk is low and is outweighed by the terminal nature of some cancers.